Alembic Pharma receives USFDA approval for Bromfenac Ophthalmic Solution

Alembic Pharmaceuticals has received USFDA approval from for Bromfenac Ophthalmic Solution, used for treatment of post-operative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. The drug is a therapeutically equivalent to the reference listed drug (RLD), Bromday Ophthalmic Solution, 0.09 per cent, of Bausch & Lomb.

According to market estimates, Bromfenac Ophthalmic Solution 0.09 per cent has an estimated market size of $ 6 million for 12 months ending December 2018.

Company Profile : Alembic Pharmaceuticals Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.